Welcome to our dedicated page for Tff Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (TFFP) has been described in its public communications as a clinical-stage biopharmaceutical company built around its proprietary Thin Film Freezing (TFF) technology platform. Over time, the company has issued news covering its inhaled dry powder product candidates, collaborations with academic and government partners, and later, significant corporate developments related to winding down operations and delisting from Nasdaq.
Earlier news from TFF Pharmaceuticals has focused on the progress of its TFF-based pipeline. This includes updates on tacrolimus inhalation powder (TFF TAC) for the prevention of lung transplant rejection, where the company has reported Phase 2 clinical data on safety, pharmacokinetics, biomarker outcomes, and patient enrollment. Additional releases have highlighted preclinical data for TFF-formulated influenza vaccine candidates and work on inhaled or intranasal dry powder formulations designed to address respiratory viral infections, including influenza and COVID, often in collaboration with institutions such as Emory University and Cleveland Clinic and with support from U.S. government agencies.
News items have also described the broader capabilities of the Thin Film Freezing platform, including its application to vaccines, small and large molecules, and biologics, and its potential to create temperature-stable dry powders suitable for inhalation or topical delivery. Corporate updates have included financial results, regulatory interactions with the U.S. Food and Drug Administration regarding the TFF TAC program, and the engagement of advisors to explore partnership and licensing opportunities.
More recent announcements mark a shift in focus, with TFF Pharmaceuticals disclosing the termination of its employees, a decision to wind down operations, and plans for liquidation and dissolution. The company has also announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market, stating that this step is being taken in connection with the planned liquidation. This news page provides a record of both the scientific and clinical developments associated with the TFF platform and the subsequent corporate decisions affecting the company’s trading status and future.
TFF Pharmaceuticals (NASDAQ: TFFP) has initiated dosing in a Phase 1b clinical trial for its Voriconazole Inhalation Powder, targeting patients with asthma. The trial will assess safety and pharmacokinetics, crucial for treatment without bronchospasm induction in hyperreactive airway patients. Previous studies showed the formulation was well tolerated in healthy volunteers. Voriconazole is highly regarded for treating Invasive Pulmonary Aspergillosis (IPA), but its oral form has significant interactions. The inhaled version aims to enhance efficacy and reduce systemic side effects, paving the way for pivotal Phase 2 studies.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) has reported its third-quarter financial results for 2020, highlighting clinical advancements in its unique Thin Film Freezing technology. The company has signed a Letter of Intent with Felix Biotechnology for developing dry powder inhalation formulations and a worldwide joint development agreement with Augmenta Bioworks for monoclonal antibodies targeting COVID-19. Additionally, TFF has achieved successful Phase 1 trial results for its Voriconazole and Tacrolimus inhalation powders. The company faced a net loss of $12.7 million for the nine months ended September 30, 2020.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) has entered into a letter of intent with Felix Biotechnology, Inc. to negotiate a collaboration for the development of a bacteriophage-based biotherapeutic using TFF's patented Thin Film Freezing technology. This agreement will allow Felix to develop dry powder formulations for inhalation delivery, with TFF receiving an upfront payment, development milestones, and royalties on sales. The collaboration aims to address antibiotic-resistant bacterial infections, with Felix currently conducting trials targeting Pseudomonas in cystic fibrosis patients.
TFF Pharmaceuticals (NASDAQ: TFFP) and Augmenta Bioworks have formed a worldwide Joint Development and Collaboration Agreement aimed at creating new therapeutics using Augmenta’s human-derived monoclonal antibodies for potential COVID-19 treatments. This partnership will leverage TFF's Thin-Film Freezing technology to develop inhalable dry powder formulations. The agreement stipulates a 50-50 split of costs and future revenues from the collaboration. Both companies are excited about the potential breakthroughs in antibody therapeutics that could emerge from this partnership.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is expanding its manufacturing capabilities through a new agreement with Experic, LLC to install a Thin Film Freezing processing line at Experic's cGMP facility in Cranbury, New Jersey. This installation, expected to be completed by early Q2-2021, aims to enhance TFF's manufacturing capacity and provide a third cGMP site. The collaboration focuses on developing additional products for pharmaceutical partners, utilizing Experic's expertise in dry powder inhalation products.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) held its Annual Meeting of Stockholders, where all director nominees were elected, and Marcum LLP was appointed as the independent auditor for the 2020 fiscal year. Approximately 83% of common shares were represented at the meeting, which was conducted virtually due to COVID-19 concerns. The election of directors saw significant support, with votes overwhelmingly in favor. The company continues to develop its TFF technology platform aimed at enhancing drug absorption for poorly water-soluble medications, with ongoing plans for collaborations with larger pharmaceutical entities.
IRISYS LLC has partnered with TFF Pharmaceuticals to manufacture an inhalable medication aimed at treating COVID-19 and other lung conditions. This is their third contract, highlighting TFF's reliance on IRISYS for the production of investigational powder products. TFF's patented Thin Film Freezing technology creates dry powder formulations suitable for inhalation, potentially improving treatment efficacy for lung infections. The process allows up to 75% of the drug to reach the deep lung. This collaboration emphasizes advancements in respiratory medicine.